Abstract: A stabilized oral dosage form of an active pharmaceutical ingredient (API) such as paroxetine hydrochloride for improving the stability of the said API prior to incorporating into an oral delivery system, and a process for preparation of free flowing granules of paroxetine hydrochloride obtained by coating them with moisture barrier pharmaceutical excipients.

Abstract: A stable fixed dose oral pharmaceutical formulation is provided. The formulation contains at least one anti-infective agent and at least one susceptible microorganism as active ingredients. At least one of the active ingredients is coated to provide a protective barrier around the active ingredient, the active ingredients being contained in a single pharmaceutical formulation. The formulation may be a tablet, a capsule, or a powder which may be made into a stable liquid. The protective barrier protectis the susceptible micro-organism from the effect of the anti-infective agent to maintain the susceptible micro-organism in a viable form for a period of at least three months. The anti-infective agent can be an antibiotic such as an amoxycillin and the microorganism can be Lactobacillus acidophilus.

Abstract: A process of making a stable fixed dose oral pharmaceutical formulation is provided. The formulation contains at least one anti-infective agent and at least one microorganism. The process involves a step of first coating the agent and/or the microorganism to provide a protective barrier around it. Next, the process involves a step of combining the agent and the microorganism into a single pharmaceutical formulation in the form of a capsule or a tablet. The barrier protects the microorganism from the effect of the anti-infective agent to maintain the microorganism in a viable form for a period of at least three months. The agent can be an antibiotic such as amoxycillin and the microorganism can be Lactobacillus acidophilus.